Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

Telomere length, arsenic exposure and risk of basal cell carcinoma of skin.

Srinivas N, Rachakonda S, Hielscher T, Calderazzo S, Rudnai P, Gurzau E, Koppova K, Fletcher T, Kumar R.

Carcinogenesis. 2019 Mar 15. pii: bgz059. doi: 10.1093/carcin/bgz059. [Epub ahead of print]

PMID:
30874287
2.

Targeting DNA gyrase to combat Mycobacterium tuberculosis: An update.

Das S, Garg T, Srinivas N, Dasgupta A, Chopra S.

Curr Top Med Chem. 2019 Mar 4. doi: 10.2174/1568026619666190304130218. [Epub ahead of print]

PMID:
30834837
3.

Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.

Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price RW, Spudich S, Swanstrom R, Kashuba ADM.

Clin Transl Sci. 2019 Jan 24. doi: 10.1111/cts.12620. [Epub ahead of print]

PMID:
30675981
4.

Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.

Giri P, Delvadia P, Ladani MK, Prajapati N, Gupta L, Patel N, Joshi V, Giri S, Jain MR, Srinivas NR, Patel PR.

Eur J Pharm Sci. 2019 Mar 15;130:107-113. doi: 10.1016/j.ejps.2019.01.005. Epub 2019 Jan 8.

PMID:
30633968
5.

Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.

Srinivas NR.

Clin Drug Investig. 2019 Jan;39(1):105-107. doi: 10.1007/s40261-018-0738-x. No abstract available.

PMID:
30632108
6.

Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes.

Patel H, Desai N, Patel P, Modi N, Soni K, Dobaria N, Srinivas NR.

Xenobiotica. 2018 Dec 27:1-7. doi: 10.1080/00498254.2018.1540805. [Epub ahead of print]

PMID:
30588869
7.

Author Correction: Telomere length and survival in primary cutaneous melanoma patients.

Rachakonda S, Srinivas N, Mahmoudpour SH, Garcia-Casado Z, Requena C, Traves V, Soriano V, Cardelli M, Pjanova D, Molven A, Gruis N, Nagore E, Kumar R.

Sci Rep. 2018 Dec 14;8(1):17963. doi: 10.1038/s41598-018-36657-w.

8.

Review of DBS methods as a quantitative tool for anticancer drugs.

Sulochana SP, Daram P, Srinivas NR, Mullangi R.

Biomed Chromatogr. 2019 Jan;33(1):e4445. doi: 10.1002/bmc.4445. Review.

PMID:
30512220
9.

Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor.

Giri P, Gupta L, Singh S, Patel N, Srinivas NR, Srivastva B, Desai RC, Patel PR.

Xenobiotica. 2018 Nov 29:1-28. doi: 10.1080/00498254.2018.1546916. [Epub ahead of print]

PMID:
30488748
10.
11.

Use of cocktail probe drugs for indexing cytochrome P450 enzymes in clinical pharmacology studies - Review of case studies.

Giri P, Patel H, Srinivas NR.

Drug Metab Lett. 2018 Nov 19. doi: 10.2174/1872312812666181119154734. [Epub ahead of print]

PMID:
30451124
12.

Incurred sample reanalysis in drug discovery bioanalysis.

Giri P, Patel N, Joshi V, Giri S, Srinivas NR.

Biomed Chromatogr. 2019 Mar;33(3):e4430. doi: 10.1002/bmc.4430. Epub 2018 Dec 6.

PMID:
30412644
13.

Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species.

Srinivas N, Rosen EP, Gilliland WM Jr, Kovarova M, Remling-Mulder L, De La Cruz G, White N, Adamson L, Schauer AP, Sykes C, Luciw P, Garcia JV, Akkina R, Kashuba ADM.

Xenobiotica. 2018 Dec 17:1-10. doi: 10.1080/00498254.2018.1539278. [Epub ahead of print]

PMID:
30346892
14.

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.

Holmström TH, Moilanen AM, Ikonen T, Björkman ML, Linnanen T, Wohlfahrt G, Karlsson S, Oksala R, Korjamo T, Samajdar S, Rajagopalan S, Chelur S, Narayanan K, Ramachandra RK, Mani J, Nair R, Gowda N, Anthony T, Dhodheri S, Mukherjee S, Ujjinamatada RK, Srinivas N, Ramachandra M, Kallio PJ.

Mol Cancer Ther. 2019 Jan;18(1):28-38. doi: 10.1158/1535-7163.MCT-18-0204. Epub 2018 Oct 9.

PMID:
30301864
15.

Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime.

Giri P, Patel H, Srinivas NR.

Drug Res (Stuttg). 2018 Oct 8. doi: 10.1055/a-0748-5548. [Epub ahead of print]

PMID:
30296806
16.

Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.

Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, Nagore E, Kumar R.

Genes Chromosomes Cancer. 2018 Nov;57(11):564-572. doi: 10.1002/gcc.22669. Epub 2018 Sep 11.

PMID:
30203894
17.

A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.

Saravu K, Tellapragada C, Kulavalli S, Xavier W, Umakanth S, Brahmarouphu G, Srinivas NK, Channabasavaiah JP, Bava A, Saadi AV, Guddattu V, Satyamoorthy K, Bhat K.

Malar J. 2018 Sep 3;17(1):321. doi: 10.1186/s12936-018-2472-5.

18.

Optimization of USSP duration for enhanced corrosion resistance of AA7075.

Pandey V, Singh JK, Chattopadhyay K, Srinivas NCS, Singh V.

Ultrasonics. 2019 Jan;91:180-192. doi: 10.1016/j.ultras.2018.08.011. Epub 2018 Aug 17.

PMID:
30146321
19.

In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.

Giri P, Gupta L, Naidu S, Joshi V, Patel N, Giri S, Srinivas NR.

Drug Metab Lett. 2018;12(2):101-116. doi: 10.2174/1872312812666180816164626.

PMID:
30117405
20.

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

Andrés-Lencina JJ, Rachakonda S, García-Casado Z, Srinivas N, Skorokhod A, Requena C, Soriano V, Kumar R, Nagore E.

Int J Cancer. 2019 Mar 1;144(5):1027-1036. doi: 10.1002/ijc.31780. Epub 2018 Oct 4.

PMID:
30070694
21.

Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.

Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.

Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25.

PMID:
30046848
22.

Telomere length and survival in primary cutaneous melanoma patients.

Rachakonda S, Srinivas N, Mahmoudpour SH, Garcia-Casado Z, Requena C, Traves V, Soriano V, Cardelli M, Pjanova D, Molven A, Gruis N, Nagore E, Kumar R.

Sci Rep. 2018 Jul 19;8(1):10947. doi: 10.1038/s41598-018-29322-9. Erratum in: Sci Rep. 2018 Dec 14;8(1):17963.

23.

Central Nervous System Infections Caused by Mycobacterium abscessus: Ventricular Shunt Infection in Two Pediatric Patients and Literature Review.

Lamb GS, Del Valle Mojica C, Srinivas N, Starke J.

Pediatr Infect Dis J. 2018 Jul 11. doi: 10.1097/INF.0000000000002146. [Epub ahead of print]

PMID:
30001229
24.

Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles.

Jairam RK, Mallurwar SR, Sulochana SP, Chandrasekar DV, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R.

Drug Res (Stuttg). 2019 Jan;69(1):32-39. doi: 10.1055/a-0640-8977. Epub 2018 Jul 11.

PMID:
29996173
25.

Carbamylated Hemoglobin can Differentiate Acute Kidney Injury from Chronic Kidney Disease.

Naresh Y, Srinivas N, Vinapamula KS, Pullaiah P, Rao PVLNS, Sivakumar V.

Indian J Nephrol. 2018 May-Jun;28(3):187-190. doi: 10.4103/ijn.IJN_341_16.

26.

Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice.

Giri P, Delvadia P, Gupta L, Trivedi P, Patel N, Sharma M, Singh J, Chatterjee A, Kadam S, Srinivas NR.

Xenobiotica. 2018 Jul 30:1-10. doi: 10.1080/00498254.2018.1485989. [Epub ahead of print]

PMID:
29873579
27.

Standard curve range for clinical sample analysis of oral bioavailability/bioequivalence studies: dilemma, introspection and strategies.

Tripathi P, Patel H, Kulshrestha T, Srinivas NR.

Bioanalysis. 2018 May 1;10(10):717-722. doi: 10.4155/bio-2018-0008. Epub 2018 May 17. No abstract available.

PMID:
29771145
28.

Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.

Dash RP, Babu RJ, Srinivas NR.

Clin Pharmacokinet. 2018 Nov;57(11):1385-1398. doi: 10.1007/s40262-018-0655-4. Review.

PMID:
29682695
29.

Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension.

Patel H, Patel P, Modi N, Patel P, Wagh Y, George A, Desai N, Srinivas NR.

Xenobiotica. 2019 Apr;49(4):415-421. doi: 10.1080/00498254.2018.1464683. Epub 2018 May 8.

PMID:
29642738
30.

Clinical Pharmacology Considerations for Development of β Lactamase Inhibitor Combination with Antibiotics.

Srinivas NR.

Drug Res (Stuttg). 2018 Sep;68(9):536-540. doi: 10.1055/a-0590-3791. Epub 2018 Apr 9.

PMID:
29631295
31.

Reduced Ketobemidone Usage in Quadratus Lumborum Block Patients After Cesarean Delivery: Clinical Pharmacology Views.

Srinivas NR.

Anesth Analg. 2018 Jul;127(1):311. doi: 10.1213/ANE.0000000000003369. No abstract available.

PMID:
29624532
32.

Lack of Translatable Proinflammatory Cytokines in Cerebrospinal Fluid in Rats With Increased Hyperalgesia With or Without Fentanyl Treatment.

Srinivas NR.

Anesth Analg. 2018 Jun;126(6):2150. doi: 10.1213/ANE.0000000000002895. No abstract available.

PMID:
29517569
33.

Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.

Joshi SN, Srinivas NR, Parmar DV.

Clin Ther. 2018 Mar;40(3):456-468.e1. doi: 10.1016/j.clinthera.2018.01.016. Epub 2018 Feb 26.

PMID:
29496320
34.

Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.

Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):373-382. doi: 10.1007/s13318-018-0466-x. Review.

PMID:
29488172
35.

Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Srinivas N, Maffuid K, Kashuba ADM.

Clin Pharmacokinet. 2018 Sep;57(9):1059-1074. doi: 10.1007/s40262-018-0632-y. Review.

PMID:
29464550
36.

Letter: high oral dose of taurine for portal hypertension in cirrhotic patients-some clinical pharmacology considerations.

Srinivas NR.

Aliment Pharmacol Ther. 2018 Mar;47(6):861-862. doi: 10.1111/apt.14513. No abstract available.

PMID:
29446135
37.

Barriers and enablers to adoption of intrauterine device as a contraceptive method: A multi-stakeholder perspective.

Mishra N, Panda M, Pyne S, Srinivas N, Pati S, Pati S.

J Family Med Prim Care. 2017 Jul-Sep;6(3):616-621. doi: 10.4103/2249-4863.222028.

38.

Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction.

Srinivas NR.

Clin Pharmacol Ther. 2018 Apr;103(4):570. doi: 10.1002/cpt.961. Epub 2018 Jan 11. No abstract available.

PMID:
29322503
39.

Enzyme-free nucleic acid dynamical systems.

Srinivas N, Parkin J, Seelig G, Winfree E, Soloveichik D.

Science. 2017 Dec 15;358(6369). pii: eaal2052. doi: 10.1126/science.aal2052.

PMID:
29242317
40.

Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.

Patel H, Giri P, Patel P, Singh S, Gupta L, Patel U, Modi N, Shah K, Jain MR, Srinivas NR, Patel P.

Xenobiotica. 2018 Dec;48(12):1268-1277. doi: 10.1080/00498254.2017.1413264. Epub 2017 Dec 22.

PMID:
29224415
41.

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.

Patel MR, Kansagra KA, Parikh DP, Parmar DV, Patel HB, Soni MM, Patil US, Patel HV, Patel JA, Gujarathi SS, Parmar KV, Srinivas NR.

Clin Drug Investig. 2018 Jan;38(1):57-65. doi: 10.1007/s40261-017-0584-2.

PMID:
29022212
42.

A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators.

Dash RP, Srinivas NR, Rais R.

Biomed Chromatogr. 2018 Jan;32(1). doi: 10.1002/bmc.4109. Epub 2017 Nov 6. Review.

PMID:
28990207
43.

Arenobufagin: A potential novel opportunity for prostate cancer treatment - Intriguing mechanistic data but some questions on in vivo translatability.

Srinivas NR.

Pharmacol Res. 2018 Feb;128:400-401. doi: 10.1016/j.phrs.2017.09.015. Epub 2017 Sep 23. No abstract available.

PMID:
28951298
44.

Comments on:"In vitro and in vivo pharmacokinetics and toxicity evaluation of curcumin incorporated titanium dioxide nanoparticles for biomedical applications".

Srinivas NR.

Chem Biol Interact. 2017 Nov 1;277:145. doi: 10.1016/j.cbi.2017.09.009. Epub 2017 Sep 14. No abstract available.

PMID:
28919306
45.

A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics.

Bhavnani SP, Sola S, Adams D, Venkateshvaran A, Dash PK, Sengupta PP; ASEF-VALUES Investigators.

JACC Cardiovasc Imaging. 2018 Apr;11(4):546-557. doi: 10.1016/j.jcmg.2017.06.019. Epub 2017 Oct 5.

PMID:
28917688
46.

A cargo-sorting DNA robot.

Thubagere AJ, Li W, Johnson RF, Chen Z, Doroudi S, Lee YL, Izatt G, Wittman S, Srinivas N, Woods D, Winfree E, Qian L.

Science. 2017 Sep 15;357(6356). pii: eaan6558. doi: 10.1126/science.aan6558.

PMID:
28912216
47.

Comments on: "Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension".

Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):1019-1021. doi: 10.1007/s13318-017-0432-z. No abstract available.

PMID:
28890991
48.

Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.

Srinivas NR.

Aliment Pharmacol Ther. 2017 Oct;46(7):706-707. doi: 10.1111/apt.14240. No abstract available.

49.

Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.

Dash RP, Rais R, Srinivas NR.

Xenobiotica. 2018 Sep;48(9):945-957. doi: 10.1080/00498254.2017.1376765. Epub 2017 Oct 13. Review.

PMID:
28876959
50.

LC-ESI-MS/MS determination of 4-methylpyrazole in dog plasma and its application to a pharmacokinetic study in dogs.

Chandrasekhar DV, Suresh PS, Dittakavi S, Hiremath RA, Bhamidipati RK, Richter W, Srinivas NR, Mullangi R.

Biomed Chromatogr. 2018 Feb;32(2). doi: 10.1002/bmc.4065. Epub 2017 Sep 25.

PMID:
28810079

Supplemental Content

Loading ...
Support Center